Tofacitinib Citrate*
-
API Product :
Tofacitinib Citrate*
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Nonsteroidal products for inflammatory skin disorders; Immunosuppressants; Respiratory System; Anti-Inflammatory And Anti-Rheumatic Products
-
Originator :
PFIZER
-
CAS No. :
477600-75-2
-
Trade Name. :
XELJANZ
-
Molecular Weight :
312.369 g/mol
-
Molecular Formula :
C16H20N6O
Application
Tofacitinib is an oral drug used for treating rheumatoid arthritis. It belongs to a class of drugs called Janus kinase (JAK) inhibitors.
General Description
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.[1][2] Common side effects include diarrhea, headache, and high blood pressure.[1] Serious side effects may include infections and the development of cancer.[1] It is in the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer.